Background/Objectives: Selumetinib, a MEK1/2 inhibitor, is commonly used for treating neurofibromatosis type 1 (NF1) and is associated with cutaneous side effects such as paronychia and periungual granulomas...PDT was administered using methyl aminolevulinate (METVIX®) as the photosensitizing agent, followed by treatment with a red LED light source (630 nm, 37 J/cm2 for 8 min and 30 s)...This case demonstrates that PDT can provide a complete resolution of symptoms with a single treatment session, offering an alternative to more invasive procedures. Further studies with larger cohorts are needed to establish PDT as a standard treatment option for this condition.